CA2873654C - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents

Process for making hydroxylated cyclopentylpyrimidine compounds Download PDF

Info

Publication number
CA2873654C
CA2873654C CA2873654A CA2873654A CA2873654C CA 2873654 C CA2873654 C CA 2873654C CA 2873654 A CA2873654 A CA 2873654A CA 2873654 A CA2873654 A CA 2873654A CA 2873654 C CA2873654 C CA 2873654C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2873654A
Other languages
English (en)
French (fr)
Other versions
CA2873654A1 (en
Inventor
David Askin
Chong Han
Jonathan W. LANE
Travis Remarchuk
Sagar Shakya
C. Gregory Sowell
Keith L. Spencer
Peter J. Stengel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CA2873654A1 publication Critical patent/CA2873654A1/en
Application granted granted Critical
Publication of CA2873654C publication Critical patent/CA2873654C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CA2873654A 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds Active CA2873654C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US61/648,473 2012-05-17
US201361785122P 2013-03-14 2013-03-14
US61/785,122 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (2)

Publication Number Publication Date
CA2873654A1 CA2873654A1 (en) 2013-11-21
CA2873654C true CA2873654C (en) 2021-06-22

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873654A Active CA2873654C (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Country Status (20)

Country Link
US (4) US9416110B2 (OSRAM)
EP (1) EP2861582B1 (OSRAM)
JP (1) JP6284928B2 (OSRAM)
KR (1) KR102067850B1 (OSRAM)
CN (1) CN104470913B (OSRAM)
AU (1) AU2013262505B2 (OSRAM)
BR (1) BR112014028589B1 (OSRAM)
CA (1) CA2873654C (OSRAM)
DK (1) DK2861582T3 (OSRAM)
ES (1) ES2582557T3 (OSRAM)
IL (1) IL235715A (OSRAM)
MX (1) MX353384B (OSRAM)
MY (1) MY169028A (OSRAM)
NZ (1) NZ702935A (OSRAM)
PL (1) PL2861582T3 (OSRAM)
RU (1) RU2643811C2 (OSRAM)
SG (1) SG11201407616TA (OSRAM)
SI (1) SI2861582T1 (OSRAM)
WO (1) WO2013173768A1 (OSRAM)
ZA (1) ZA201409261B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
BR112014028593A2 (pt) 2012-05-17 2017-12-19 Genentech Inc forma amorfa de um composto de pirimidinil-ciclopentano inibidor de akt, composições e métodos dos mesmos"
AU2013262521B2 (en) 2012-05-17 2017-03-02 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
JP6214636B2 (ja) 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
HUE063095T2 (hu) * 2013-11-15 2023-12-28 Hoffmann La Roche Eljárások pirimidinilciklopentán vegyületek elõállítására
SG10201806450SA (en) * 2014-09-26 2018-09-27 Hoffmann La Roche PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
EP4613333A3 (en) 2016-08-10 2025-10-29 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
IL295929A (en) * 2020-06-16 2022-10-01 Hoffmann La Roche Process for making hydroxylated cyclopentylpyrimidine compounds
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (en) 1993-12-12 1995-06-15 Yigal Cohen A novel method to protect plants from fungal infection
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
AU3386600A (en) 1999-03-03 2000-09-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1281604C (zh) * 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Akt阻害剤
PT2592933T (pt) 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
BR112014028593A2 (pt) 2012-05-17 2017-12-19 Genentech Inc forma amorfa de um composto de pirimidinil-ciclopentano inibidor de akt, composições e métodos dos mesmos"
CA2873658C (en) 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
AU2013262521B2 (en) 2012-05-17 2017-03-02 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
JP6214636B2 (ja) 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
CA2901577A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014150395A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
US9790190B2 (en) 2017-10-17
CA2873654A1 (en) 2013-11-21
DK2861582T3 (en) 2016-08-22
MY169028A (en) 2019-02-04
NZ702935A (en) 2017-02-24
BR112014028589B1 (pt) 2022-08-23
US20170247337A1 (en) 2017-08-31
ES2582557T3 (es) 2016-09-13
IL235715A (en) 2017-02-28
CN104470913A (zh) 2015-03-25
ZA201409261B (en) 2017-05-31
KR20150020214A (ko) 2015-02-25
CN104470913B (zh) 2018-07-20
AU2013262505A1 (en) 2015-01-22
HK1208451A1 (en) 2016-03-04
MX353384B (es) 2018-01-10
RU2014151050A (ru) 2016-07-10
BR112014028589A2 (pt) 2017-07-25
SG11201407616TA (en) 2015-03-30
US9416110B2 (en) 2016-08-16
PL2861582T3 (pl) 2016-11-30
US20180258054A1 (en) 2018-09-13
WO2013173768A1 (en) 2013-11-21
EP2861582B1 (en) 2016-05-25
SI2861582T1 (sl) 2016-09-30
US20150152067A1 (en) 2015-06-04
JP6284928B2 (ja) 2018-02-28
US20160318877A1 (en) 2016-11-03
RU2643811C2 (ru) 2018-02-06
MX2014013862A (es) 2015-05-07
KR102067850B1 (ko) 2020-01-17
EP2861582A1 (en) 2015-04-22
US9676730B2 (en) 2017-06-13
JP2015517532A (ja) 2015-06-22
IL235715A0 (en) 2015-02-01
AU2013262505B2 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
CA2873654C (en) Process for making hydroxylated cyclopentylpyrimidine compounds
EP2850054B1 (en) Process for making amino acid compounds
AU2019253849B2 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208857B (en) Process for making amino acid compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180515